{"id":"W4211087830","doi":"10.1016/s0140-6736(14)61947-4","title":"Prostate cancer","year":2015,"lang":"en","type":"review","venue":"The Lancet","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":917,"is_retracted":false,"has_abstract":false,"ca_institutions":"University of Toronto; Princess Margaret Cancer Centre","funders":"Astellas Pharma; National Cancer Institute; Cancer Research UK; Prostate Cancer UK; Ipsen; National Institute for Health and Care Research; GlaxoSmithKline","keywords":"Prostate cancer; Overdiagnosis; Medicine; Docetaxel; Oncology; Internal medicine; Disease; Cancer; Prostate; Cabazitaxel; Androgen deprivation therapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.2293748849616526,"score_gpt":0.4760491146759444,"score_spread":0.2466742297142918,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}